source
- Charles River CEO predicts more manufacturers will spin off cell and gene therapy unitsCharles River Laboratories announced three months ago that it would divest its manufacturing unit dedicated to cell and gene therapy production. CEO Birgit Girshick said the company expects it wil…
- China gene-editing startup YolTech secures $70 million funding ahead of Hong Kong IPO plansYolTech Therapeutics, a Chinese company focused on CRISPR gene-editing therapies, announced it has closed a $70 million financing round, the largest in its history. The capital will be used to adv…